ABSTRACT
@#AIM: To investigate the clinical effect of vitamin A Palmitate Eye Gel combined with Tobramycin Eye Drops on corneal epithelial injury.<p>METHODS: Totally 80 patients(100 eyes)with corneal epithelial injury who came to our hospital from May 2015 to March 2016 were randomly divided into treatment group(50 eyes)and control group(50 eyes). The treatment group was treated with vitamin A Palmitate Eye Gel combined with Tobramycin Eye Drops, while the control group was treated with Tobramycin Eye Drops only. The curative effect of two groups was compared after 2wk and 4wk of treatment.<p>RESULTS: The cure rate was 80% and the effective rate was 94% in the treatment group. The cure rate was 70% and the effective rate was 78% in the control group. There was significant difference in the effective rate between the two groups(<i>P</i><0.05). The results of SⅠt and BUT test showed that the time of treatment group was significantly longer than that of control group(<i>P<</i>0.01). The score of symptoms and signs in the treatment group was significantly lower than that in the control group after 2wk of treatment(<i>P<</i>0.01), but there was no significant between treatment groups and control grouop after 4wk of treatment(<i>P></i>0.05).<p>CONCLUSION: Vitamin A Palmitate Eye Gel combined with Tobramycin Eye Drops can significantly improve dry eye symptoms and effectively shorten the healing time of corneal epithelium. It is an effective method to treat corneal epithelial injury.
ABSTRACT
This study aimed to investigate the clinical effect of transplantation of CD133⁺ peripheral blood stem cells or umbilical cord mesenchymal stem cells via the hepatic artery in children with type II hyperammonemia and its possible action mechanism. Umbilical cord mesenchymal stem cells were obtained by collecting cord blood (100-150 mL) from healthy fetuses and separating stem cell suspension (5 mL) from the cord blood by hydroxyethyl starch sedimentation. CD133⁺ peripheral blood stem cells were obtained by mobilizing peripheral blood from the fathers of sick children using recombinant human granulocyte colony-stimulating factor for 5 days, collecting mononuclear cells (120 mL), and separating out CD133⁺ cells by sorting. With catheterization and percutaneous puncture, the obtained stem cells were slowly injected into the liver of sick children via the hepatic artery. The changes in clinical symptoms and laboratory indices such as blood ammonia, liver function, and arginine and citrulline concentrations were observed. After stem cell transplantation via the hepatic artery, the 6 children showed significantly decreased blood ammonia levels, and their blood ammonia levels slowly increased 1 to 2 weeks later, but remained below 100 μmol/L, and changes in glutamic-pyruvic transaminase levels were similar to blood ammonia. Plasma citrulline and arginine concentrations increased significantly after transplantation and the increase in citrulline level exceeded the increase in arginine level. An 8 months follow-up visit for one typical patient showed that the weight and height increased after transplantation and sleep was improved without night crying. The child could actively gaze at interesting objects instead of responding indifferently and started to say simple words. With regard to fine motor skills, the child could pinch things with the thumb and middle finger instead of displaying a lack of hand-eye coordination and progress was also made in gross motor skills. Gesell test showed that the child made progress for an average of 3.82 months in all areas. It was concluded that after stem cell transplantation, children with type II hyperammonemia have decreased blood ammonia levels, stable and improved liver function and steadily increased plasma citrulline and arginine concentrations. They display a progressive trend in such aspects as movement, language and environmental adaptability. It is hypothesized that stem cell transplantation via the hepatic artery partially or totally activates, or provides supplementary ornithine carbamoyl transferase, so that plasma citrulline and arginine concentrations increase and urea cycle disorder can be corrected to some extent.
Subject(s)
Female , Humans , Infant , Male , AC133 Antigen , Ammonia , Blood , Antigens, CD , Arginine , Blood , Citrulline , Blood , Glycoproteins , Hepatic Artery , Hyperammonemia , Blood , General Surgery , Peptides , Stem Cell TransplantationABSTRACT
<p><b>OBJECTIVE</b>Severe newborn hypoxic-ischemic encephalopathy (HIE) has a very high rate of disability and no effective treatment is available. The present study aimed to preliminarily evaluate the effects of human neural stem cell transplantation in treatment of severe neonatal HIE.</p><p><b>METHODS</b>The patient was a 75-day old male infant with sequelae of severe HIE who had highly delayed development of intelligence and movement and myotonia. MRI showed multiple cerebromalacia and encephalatrophy. Cells obtained from the forebrain of an 11-week old fetus were cultured and amplified for 15 days. And then the human fetal neural stem cells were injected into cerebral ventricle of this infant.</p><p><b>RESULTS</b>Twenty eight days after transplantation, remarkable improvement occurred not only in his myotonia but also in his intelligence and movement, which became similar to those of the normal infants of the same age. Positron emission tomography (PET) showed significantly increased radioactivity at temporal and occipital lobes which suggested that the cellular metabolism had increased greatly.</p><p><b>CONCLUSION</b>The short-term effect of NSCs transplantation on the infant with severe HIE sequelae was significant. PET suggested that the implanted NSCs survived. Many more studies are needed to evaluate long-term effects of NSC transplantation in treatment of HIE.</p>